GlassScriptPhysician profile
Timothy Hodges
NPI 1225027253
$2,150.68
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,897 · 2020: $229 · 2021: $11.76 · 2022: $13.05.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $274.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.06 | 2019-2020 | |
| Amgen INC. | $211.23 | 2019 | |
| Novo Nordisk INC | $199.84 | 2019-2020 | |
| Allergan, INC. | $199.37 | 2019 | |
| Astellas Pharma US INC | $169.21 | 2019 | |
| Pfizer INC. | $154.65 | 2019 | |
| Lilly USA, LLC | $104.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.89 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.93 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $33.67 | 2019-2020 | |
| Antares Pharma, INC. | $31.47 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.51 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.73 | 2019 | |
| Medtronic USA, INC. | $15.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.05 | 2019 | |
| Abbott Laboratories | $14.52 | 2020 | |
| Therapeuticsmd, INC. | $14.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.50 | 2019 | |
| Abbvie INC. | $13.05 | 2022 | |
| Amneal Pharmaceuticals LLC | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.